Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults (COVID-19)
Phase I Study Evaluating the Basic Pharmacological and Toxicological Effects of the Protective VLP Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously, in Two Different Dosages.
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Listed as NCT04818281, this PHASE1 trial focuses on Covid19 and remains completed. Sponsored by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, it has been updated 7 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2021 — Jun 2022 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Ihsan GURSEL, PhD, Prof.
- MonitorCRO
- Nobel Pharmaceuticals
- The Scientific and Technological Research Council of Turkey
For direct contact, visit the study record on ClinicalTrials.gov .